Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens

Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2022-02, Vol.57 (2), p.232-242
Hauptverfasser:	Yao, Janny M., Yang, Dongyun, Clark, Mary C., Otoukesh, Salman, Cao, Thai, Ali, Haris, Arslan, Shukaib, Aldoss, Ibrahim, Artz, Andrew, Amanam, Idoroenyi, Salhotra, Amandeep, Pullarkat, Vinod, Sandhu, Karamjeet, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Al Malki, Monzr M.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059 692/308/575 Cell Biology Cyclophosphamide Cyclophosphamide - therapeutic use Disease prevention Graft versus host disease Graft vs Host Disease - etiology Graft-versus-host reaction Health risks Hematology Hematopoietic Stem Cell Transplantation - adverse effects Humans Infections Internal Medicine Medicine Medicine & Public Health Neoplasm Recurrence, Local - drug therapy Prophylaxis Public Health Retrospective Studies Serum levels Steady state Stem cell transplantation Stem Cells Survival Tacrolimus Tacrolimus - therapeutic use Toxicity Transplantation Transplants & implants Viral infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady state (TISS) of
ISSN:	0268-3369 1476-5365
DOI:	10.1038/s41409-021-01528-y